A Breakthrough in Psoriasis Treatment <\/p>\n
Plaque psoriasis, a chronic skin condition characterized by patches of abnormal skin, often brings about significant discomfort and distress to those affected. The search for an effective treatment has led to a promising discovery: JNJ-77242113, an interleukin-23-receptor antagonist peptide. According to a study published in the New England Journal of Medicine, this innovative oral medication has shown greater efficacy than a placebo in patients suffering from moderate-to-severe plaque psoriasis. <\/p>\n
The phase 2 dose-finding trial involved 255 patients and revealed a significant dose-response relationship. This means that higher doses of JNJ-77242113 resulted in a greater therapeutic effect. Remarkably, a higher percentage of patients receiving JNJ-77242113 showed a Psoriasis Area and Severity Index (PASI) 75 response compared to those in the placebo group. PASI 75 response refers to a 75% reduction in the PASI score, a tool used to measure the severity and extent of psoriasis. This achievement serves as the primary endpoint of the trial, marking a significant milestone in psoriasis treatment. <\/p>\n
The potency of JNJ-77242113 was clearly demonstrated, with 79 percent of patients in the highest dose group achieving a PASI 75 response at Week 16. This impressive result signals a potential game-changer for those battling moderate to severe plaque psoriasis. Furthermore, the study found no evidence of a dose-related increase in adverse events across the JNJ-77242113 dose groups, suggesting that even at higher doses, the treatment maintains a favourable safety profile. <\/p>\n
The most common adverse events reported during the trial were COVID-19 and nasopharyngitis, a common infection resulting in inflammation of the nasal passages and throat. Its important to note that similar percentages of patients experienced adverse events in both the JNJ-77242113 and placebo groups. The occurrence of these events is not surprising given the ongoing COVID-19 pandemic and the common nature of nasopharyngitis. <\/p>\n
The positive results from this phase 2 trial have spurred further research and development. Janssen Research and Development, the company behind JNJ-77242113, has initiated the Phase 3 ICONIC clinical development program. This program, which includes two studies, aims to further assess the efficacy and safety of JNJ-77242113 in adults and adolescents suffering from moderate to severe plaque psoriasis. <\/p>\n
Overall, the results of this study are promising. The development and successful trial of JNJ-77242113 mark a significant advancement in the treatment of moderate-to-severe plaque psoriasis. With ongoing research, there is hope that this medication may revolutionize treatment options and bring much-needed relief to those affected by this often debilitating skin condition. <\/p>\n
<\/p>\n
The rest is here: A Breakthrough in Psoriasis Treatment Plaque psoriasis, a chronic skin condition characterized by patches of abnormal skin, often brings about significant discomfort and distress to those affected. The search for an effective treatment has led to a promising discovery: JNJ-77242113, an interleukin-23-receptor antagonist peptide. According to a study published in the New England Journal of Medicine, this innovative oral medication has shown greater efficacy than a placebo in patients suffering from moderate-to-severe plaque psoriasis Continue reading
\nBreakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"